Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Ecovyst
ECVT
$1.09B
| $675K | ﹤0.01% |
51,000
-84,200
| -62% | -$989K |
|
|
LITB
2752
LightInTheBox
LITB
$56.7M
| $673K | ﹤0.01% |
127,737
+50,700
| +66% | +$242K |
|
2753
Traws Pharma
TRAW
$8.12M
| $672K | ﹤0.01% |
+3,166
| New | +$484K |
|
2754
Invesco S&P SmallCap Low Volatility ETF
XSLV
$250M
| $670K | ﹤0.01% |
19,800
-1,600
| -7% | -$53.1K |
|
|
ATXS
2755
DELISTED
Astria Therapeutics
ATXS
| $669K | ﹤0.01% |
17,341
+7,953
| +85% | +$283K |
|
|
VBIV
2756
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $666K | ﹤0.01% |
7,163
-4,264
| -37% | -$235K |
|
|
KWY
2757
Kingsway Corp
KWY
$283M
| $665K | ﹤0.01% |
297,142
+32,682
| +12% | +$65K |
|
|
AGEN
2758
Agenus
AGEN
$315M
| $664K | ﹤0.01% |
8,613
-15,320
| -64% | -$917K |
|
|
ACCS
2759
ACCESS Newswire
ACCS
$20M
| $663K | ﹤0.01% |
+65,338
| New | +$658K |
|
|
NBEV
2760
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
| $663K | ﹤0.01% |
+433,590
| New | +$647K |
|
|
GORV
2761
DELISTED
Lazydays
GORV
| $662K | ﹤0.01% |
+2,533
| New | +$370K |
|
2762
Marker Therapeutics
MRKR
$18.5M
| $662K | ﹤0.01% |
31,962
+8,492
| +36% | +$186K |
|
2763
Vanguard Consumer Discretionary ETF
VCR
$6.11B
| $660K | ﹤0.01% |
+3,300
| New | +$595K |
|
2764
iShares Morningstar Growth ETF
ILCG
$3.3B
| $657K | ﹤0.01% |
+14,000
| New | +$608K |
|
|
ATRS
2765
DELISTED
Antares Pharma, Inc.
ATRS
| $653K | ﹤0.01% |
237,528
-1,129,086
| -83% | -$3.15M |
|
2766
Vanguard S&P 500 ETF
VOO
$1.04T
| $652K | ﹤0.01% |
2,300
-2,800
| -55% | -$754K |
|
2767
ImmuCell
ICCC
$99.3M
| $651K | ﹤0.01% |
137,672
+19,800
| +17% | +$86.3K |
|
|
PHLT
2768
DELISTED
Performant Healthcare Inc
PHLT
| $650K | ﹤0.01% |
995,939
+33,200
| +3% | +$22.9K |
|
|
AINC
2769
DELISTED
Ashford Inc.
AINC
| $649K | ﹤0.01% |
63,924
+4,941
| +8% | +$40.9K |
|
2770
J. Jill
JILL
$279M
| $647K | ﹤0.01% |
187,084
+42,323
| +29% | +$115K |
|
|
AFBI
2771
DELISTED
Affinity Bancshares
AFBI
| $646K | ﹤0.01% |
70,272
-22
| -0% | -$183 |
|
2772
Tenax Therapeutics
TENX
$68.5M
| $646K | ﹤0.01% |
446
+83
| +23% | +$122K |
|
2773
Dare Bioscience
DARE
$20.5M
| $645K | ﹤0.01% |
54,340
+37,589
| +224% | +$461K |
|
2774
Direxion Daily MSCI Emerging Markets Bear 3X ETF
EDZ
$18.5M
| $641K | ﹤0.01% |
+2,450
| New | +$859K |
|
2775
Build-A-Bear
BBW
$474M
| $639K | ﹤0.01% |
293,079
-75,403
| -20% | -$162K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.